North Immunology joins biotech reverse merger boom with Aethlon deal
Source ↗
👁 0
💬 0
Armed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.
Comments (0)